Attending the 2nd World Congress on Biologics and Biosimilars 2027 in Vienna, Austria, offers a valuable opportunity for scientists, researchers, healthcare professionals, pharmaceutical industry leaders, regulatory experts, academicians, and biotechnology innovators to explore the latest developments in biologics and biosimilar medicines. Scheduled for September 27–28, 2027, this international congress will provide a platform for scientific exchange, interdisciplinary collaboration, and professional networking, bringing together experts committed to advancing biopharmaceutical research and improving patient access to innovative therapies.
As biologic medicines continue to transform the treatment of complex and chronic diseases, the development of high-quality, safe, and effective biosimilars has become increasingly important. The congress will focus on emerging scientific innovations, advances in biopharmaceutical development and manufacturing, regulatory pathways, analytical characterization, clinical evaluation, immunogenicity, quality assurance, and the evolving role of biosimilars in modern healthcare. Discussions will also explore strategies to address scientific and regulatory challenges, strengthen industry–academia partnerships, and support the broader adoption of biologic and biosimilar therapies worldwide.
The congress will feature scientific presentations, keynote lectures, oral and poster presentations, expert discussions, and opportunities for professional engagement. These sessions will enable established researchers and early-career scientists to share their findings, present innovative approaches, exchange perspectives, and receive valuable feedback from peers and subject-matter experts. Participants will also have opportunities to explore emerging research trends, discuss practical challenges, establish collaborative relationships, and identify new possibilities for scientific and commercial advancement in the biopharmaceutical sector.
By bringing together professionals from academia, biotechnology, pharmaceutical companies, healthcare institutions, and regulatory organizations, the congress aims to encourage meaningful dialogue and promote scientific excellence throughout the biologics and biosimilars landscape.
Vienna, Austria, provides an international setting for scientific exchange, innovation, and collaboration. Recognized for its rich academic heritage, international outlook, and strong conference infrastructure, the city offers an ideal environment for bringing together experts from diverse scientific and professional backgrounds. Its central European location also makes it an accessible destination for participants traveling from different parts of the world, creating opportunities to build global connections and strengthen international research partnerships.
The 2nd World Congress on Biologics and Biosimilars 2027 aims to advance scientific knowledge, encourage innovation, and strengthen collaboration across the global biopharmaceutical community. Under the theme “Advancing Biologics and Biosimilars Through Innovation and Scientific Excellence,” the congress will provide a forum to discuss emerging discoveries, address current challenges, and explore opportunities that can contribute to the development of effective, high-quality, and accessible biologic and biosimilar medicines.
Whether you are a researcher investigating novel biologic therapies, a scientist working in biosimilar development, a regulatory professional, a healthcare practitioner, an academician, or an industry representative, your participation can contribute to valuable scientific discussions and future collaborations.
We warmly invite you to join us in Vienna, Austria, on September 27–28, 2027, and become part of this international scientific gathering. Submit your abstract, present your research, participate as a speaker or delegate, or explore exhibition and collaboration opportunities to share your expertise and connect with professionals shaping the future of biologics and biosimilars.
Be part of the conversation. Share your research. Help shape the future of biologic and biosimilar innovation.
Visit the official conference website: https://biosimilars.novelticsconferences.com/
Discover a constellation of brilliance with our curated selection of 50+ extraordinary speakers! From industry titans to influential thought leaders, these luminaries ignite inspiration and drive change across diverse arenas. Uncover groundbreaking insights from tech innovators, absorb wisdom from visionary leaders, and be moved by impassioned storytellers. Join this unparalleled gathering of minds as they share expertise, motivate change, and reshape the world with their unparalleled knowledge and visionary outlooks!
Find Out MoreUnveiling a cadre of 15+ exceptional keynote speakers, each a beacon of insight and inspiration! These thought leaders and visionaries bring diverse expertise, from cutting-edge tech to transformative leadership strategies. Engage with their captivating narratives, glean wisdom from their experiences, and absorb their visionary perspectives. Join this exclusive assembly of minds poised to ignite motivation, drive change, and chart new frontiers in innovation, leadership, and personal growth!
Find Out MoreEmbark on a dynamic journey with our array of 10+ immersive workshops and exhibitions! Dive into hands-on sessions led by industry experts, unlocking new skills and strategies in diverse fields. Explore interactive exhibits showcasing cutting-edge technologies, innovative products, and groundbreaking ideas. Engage, learn, and network in these vibrant spaces, gaining invaluable insights and forging connections that inspire growth, innovation, and advancement across various industries!
Find Out MoreBiologics and biosimilars are transforming modern medicine by advancing the treatment of complex diseases, including cancer, autoimmune disorders, and chronic conditions. Biologics are medicines derived from living organisms, while biosimilars are highly similar versions of approved biological medicines with no clinically meaningful differences in safety, purity, and potency. Ongoing research, innovative manufacturing technologies, and evolving regulatory frameworks continue to expand their role in improving patient access to effective and affordable therapies.
Session 02: Current Challenges in Developing BiosimilarsDeveloping biosimilars involves complex scientific, technical, and regulatory challenges, including demonstrating high similarity to reference biologics, managing manufacturing variability, assessing immunogenicity, and ensuring consistent product quality and safety. Advances in analytical technologies, clinical evaluation, and manufacturing processes are helping researchers address these challenges, improve development efficiency, and expand patient access to affordable biologic therapies.
Session 03: Intellectual Property RightsIntellectual Property Rights (IPR) play a crucial role in the development and commercialization of biologics and biosimilars. This topic explores patent protection, regulatory exclusivity, licensing agreements, and intellectual property challenges, supporting innovation while encouraging competition and broader access to affordable biologic medicines.
Session 04: Biomarkers and ResearchExplore the role of biomarkers in advancing biologics and biosimilars research, improving disease diagnosis, evaluating treatment responses, and assessing drug safety and efficacy. Discover innovative biomarker-based approaches that support precision medicine, clinical development, and the advancement of targeted therapies.
Session 05: Biological MedicineBiological Medicine focuses on the development and application of medicines derived from living organisms, such as proteins, antibodies, and other biological substances. These therapies play a vital role in treating complex diseases, including cancer, autoimmune disorders, and chronic inflammatory conditions. Advances in biotechnology continue to improve the safety, effectiveness, and accessibility of biological medicines, including biosimilars, contributing to the future of personalized and precision medicine.
Session 06: Brexit EffectBrexit has significantly influenced the pharmaceutical and biotechnology sectors by changing regulatory frameworks, trade relationships, and market access between the UK and the European Union. For biologics and biosimilars, these changes affect drug approval procedures, clinical trials, supply chains, and pharmaceutical market strategies. Understanding the impact of Brexit is essential for ensuring regulatory compliance, maintaining efficient product distribution, and supporting innovation in the evolving European biopharmaceutical industry.
Session 07: Regulatory Updates on BiosimilarsExplore the latest regulatory guidelines, approval pathways, and evolving global standards for biosimilars. Discuss regulatory harmonization, quality assurance, clinical evaluation, and safety requirements shaping the development, approval, and commercialization of biosimilar products worldwide.
Session 08: Biosimilars Development in MarketsBiosimilar development is expanding global healthcare markets by improving access to effective, high-quality, and affordable biological medicines. Advances in research, manufacturing, regulatory pathways, and commercialization are creating new opportunities for pharmaceutical companies while encouraging competition and supporting sustainable healthcare systems.
Session 09: Biopharmaceutical InformaticsBiopharmaceutical Informatics integrates bioinformatics, data analytics, computational biology, and digital technologies to support the research, development, and manufacturing of biologics and biosimilars. It enables data-driven decision-making, improves drug development efficiency, supports quality control, and accelerates the delivery of safe and effective biopharmaceutical products.
Session 10: Biosimilars Market and Cost AnalysisExplore the evolving biosimilars market, pricing strategies, manufacturing costs, and economic benefits of biosimilar adoption. Examine market trends, cost-effectiveness, competition, and opportunities to improve patient access to affordable biological therapies worldwide.
Session 11: Challenges in Biosimilars PharmacovigilanceBiosimilars pharmacovigilance plays a vital role in monitoring the safety and effectiveness of biosimilar medicines after approval. Key challenges include distinguishing adverse drug reactions between reference biologics and biosimilars, ensuring accurate product traceability, assessing immunogenicity, and collecting reliable real-world safety data. Effective monitoring systems, clear reporting practices, and strong regulatory collaboration are essential to ensure patient safety and maintain confidence in biosimilar therapies.
Session 12: Globalization of BiosimilarsThe globalization of biosimilars is expanding access to affordable biologic medicines across international markets. Harmonized regulatory frameworks, cross-border collaborations, and advances in manufacturing are helping accelerate biosimilar development and adoption worldwide. Addressing challenges related to regulatory differences, market access, and public confidence is essential to promoting sustainable growth and improving global healthcare accessibility.
Session 13: Drug Delivery and DevelopmentDrug Delivery and Development focuses on innovative strategies for designing, formulating, and delivering biologics and biosimilars safely and effectively. It explores advanced delivery systems, targeted therapies, formulation optimization, and emerging technologies that enhance drug stability, bioavailability, therapeutic efficacy, and patient outcomes.
Session 14: AI and Data Analytics in Biologic ResearchArtificial intelligence (AI) and data analytics are transforming biologic research by accelerating drug discovery, improving protein structure prediction, optimizing bioprocesses, and enabling data-driven decision-making. These technologies support the development of innovative biologics and biosimilars, enhance research efficiency, and help advance precision medicine and therapeutic development.
Session 15: USFDA Approved BiosimilarsUSFDA-approved biosimilars are biological products demonstrated to be highly similar to an FDA-approved reference biologic, with no clinically meaningful differences in safety, purity, and potency. They expand access to effective treatments for conditions such as cancer, autoimmune diseases, and diabetes while supporting affordability and competition in healthcare. Ongoing research, regulatory advances, and manufacturing innovation continue to shape the development and adoption of biosimilars.
Unlock Boundless Insights and Connect with Global Experts—Register Now to Join the Transformative Experience!
